Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?

Research output: Article

4 Citations (Scopus)

Abstract

Combined inhibition of platelet aggregation is essential to prevent recurrent ischemic episodes in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). In combination with aspirin, the ADP receptor antagonist clopidogrel is used widespread for this purpose; however, platelet reactivity after clopidogrel differs substantially between patients and high on-treatment platelet reactivity (HTPR) persists in a substantial proportion of cases. Since more than 20 prior observational studies linked HTPR to higher risk of ischemic events, including cardiovascular death, myocardial infarction, and stent thrombosis, monitoring post-clopidogrel platelet reactivity after PCI might be beneficial for risk assessment and to tailor the antiplatelet therapy to the patients' needs. However, there is no consensus on the role of routine platelet function monitoring in clinical guidelines. This article aims to review the available evidence regarding the clinical relevance of platelet function monitoring, highlighting possible reasons for the controversy between guidelines and observational studies.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalPlatelets
Volume23
Issue number3
DOIs
Publication statusPublished - máj. 2012

Fingerprint

clopidogrel
Physiologic Monitoring
Blood Platelets
Percutaneous Coronary Intervention
Observational Studies
Purinergic P2Y Receptor Antagonists
Guidelines
Acute Coronary Syndrome
Platelet Aggregation
Aspirin
Stents
Thrombosis
Therapeutics
Myocardial Infarction

ASJC Scopus subject areas

  • Hematology

Cite this

@article{17045739cad5483bbdeb46eb9113cb19,
title = "Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?",
abstract = "Combined inhibition of platelet aggregation is essential to prevent recurrent ischemic episodes in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). In combination with aspirin, the ADP receptor antagonist clopidogrel is used widespread for this purpose; however, platelet reactivity after clopidogrel differs substantially between patients and high on-treatment platelet reactivity (HTPR) persists in a substantial proportion of cases. Since more than 20 prior observational studies linked HTPR to higher risk of ischemic events, including cardiovascular death, myocardial infarction, and stent thrombosis, monitoring post-clopidogrel platelet reactivity after PCI might be beneficial for risk assessment and to tailor the antiplatelet therapy to the patients' needs. However, there is no consensus on the role of routine platelet function monitoring in clinical guidelines. This article aims to review the available evidence regarding the clinical relevance of platelet function monitoring, highlighting possible reasons for the controversy between guidelines and observational studies.",
keywords = "Clopidogrel, GRAVITAS, High platelet reactivity, Outcome, Platelet function device",
author = "D. Aradi and A. Kom{\'o}csi",
year = "2012",
month = "5",
doi = "10.3109/09537104.2011.610475",
language = "English",
volume = "23",
pages = "167--176",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Platelet function monitoring in patients on clopidogrel

T2 - What should we learn from GRAVITAS?

AU - Aradi, D.

AU - Komócsi, A.

PY - 2012/5

Y1 - 2012/5

N2 - Combined inhibition of platelet aggregation is essential to prevent recurrent ischemic episodes in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). In combination with aspirin, the ADP receptor antagonist clopidogrel is used widespread for this purpose; however, platelet reactivity after clopidogrel differs substantially between patients and high on-treatment platelet reactivity (HTPR) persists in a substantial proportion of cases. Since more than 20 prior observational studies linked HTPR to higher risk of ischemic events, including cardiovascular death, myocardial infarction, and stent thrombosis, monitoring post-clopidogrel platelet reactivity after PCI might be beneficial for risk assessment and to tailor the antiplatelet therapy to the patients' needs. However, there is no consensus on the role of routine platelet function monitoring in clinical guidelines. This article aims to review the available evidence regarding the clinical relevance of platelet function monitoring, highlighting possible reasons for the controversy between guidelines and observational studies.

AB - Combined inhibition of platelet aggregation is essential to prevent recurrent ischemic episodes in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). In combination with aspirin, the ADP receptor antagonist clopidogrel is used widespread for this purpose; however, platelet reactivity after clopidogrel differs substantially between patients and high on-treatment platelet reactivity (HTPR) persists in a substantial proportion of cases. Since more than 20 prior observational studies linked HTPR to higher risk of ischemic events, including cardiovascular death, myocardial infarction, and stent thrombosis, monitoring post-clopidogrel platelet reactivity after PCI might be beneficial for risk assessment and to tailor the antiplatelet therapy to the patients' needs. However, there is no consensus on the role of routine platelet function monitoring in clinical guidelines. This article aims to review the available evidence regarding the clinical relevance of platelet function monitoring, highlighting possible reasons for the controversy between guidelines and observational studies.

KW - Clopidogrel

KW - GRAVITAS

KW - High platelet reactivity

KW - Outcome

KW - Platelet function device

UR - http://www.scopus.com/inward/record.url?scp=84859779716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859779716&partnerID=8YFLogxK

U2 - 10.3109/09537104.2011.610475

DO - 10.3109/09537104.2011.610475

M3 - Article

C2 - 21958190

AN - SCOPUS:84859779716

VL - 23

SP - 167

EP - 176

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 3

ER -